AIR Awarded $28 Million Contract to Enhance Accessibility of Cell and Gene Therapy for Medicaid Recipients

Aug 22, 2024

Arlington, Va., Aug. 21, 2024– The American Institutes for Research (AIR) has been awarded a significant federal contract by the Center for Medicare and Medicaid Innovation (CMMI) under the Centers for Medicare and Medicaid Services (CMS) to assist in the implementation and monitoring of a transformative new program. This initiative, known as the Cell and Gene Therapy (CGT) Access Model, is designed to improve the accessibility of cutting-edge CGT treatments for Medicaid recipients.
Cell and Gene Therapy
Under the $28 million contract, AIR’s experts will support the CGT Access Model, a program aimed at evaluating the effectiveness of outcomes-based agreements (OBAs) negotiated and administered by CMS and state-led approaches. The goal is to enhance access to these innovative treatments, improve health outcomes for Medicaid patients, reduce overall healthcare costs, and promote health equity.

The initial focus of the CGT Access Model will be on Sickle Cell Disease (SCD), a genetic blood disorder that predominantly affects Black Americans, impacting over 100,000 people in the U.S. SCD patients often endure severe pain, leading to frequent hospitalizations, and have a life expectancy 20 years shorter than the national average.

AIR’s role will be crucial in monitoring the implementation and outcomes of the CGT Access Model. The organization will develop and execute a comprehensive data collection and analysis plan to assess both health outcomes and financial indicators. AIR’s efforts will also include disseminating findings at conferences to foster innovation in the field.

“The Cell and Gene Therapy Access Model has the potential to make groundbreaking treatments more widely available to those who need them and reduce long-term healthcare costs,” said Timothy Hill, AIR senior vice president, who leads the institution’s Health Division. “We look forward to working with CMS and our partners to test innovative solutions that can improve people’s lives and create a more equitable world.”

Source:
https://www.globenewswire.com/news-release/2024/08/21/2933709/0/en/American-Institutes-for-Research-To-Help-Implement-Federal-Program-Aimed-at-Increasing-Access-to-Transformative-Cell-and-Gene-Therapy-Treatments.html
GMP mRNA
Check out our AAV CDMO service to expedite your gene therapy research
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.
READ MORE

AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
READ MORE
aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.
READ MORE